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Abstract
In contrast to the genetic component in mammary carcinogenesis, epigenetic alterations are particularly important for the
development of sporadic breast cancer (BC) comprising over 90% of all BC cases worldwide. Most of the DNA methylation
processes are physiological and essential for human cellular and tissue homeostasis, playing an important role in a number of key
mechanisms. However, if dysregulated, DNAmethylation contributes to pathological processes such as cancer development and
progression. A global hypomethylation of oncogenes and hypermethylation of tumor-suppressor genes are characteristic of most
cancer types. Moreover, histone chemical modifications and non-coding RNA-associated multi-gene controls are considered as
the key epigenetic mechanisms governing the cellular homeostasis and differentiation states. A number of studies demonstrate
dietary plant products as actively affecting the development and progression of cancer. BNutri-epigenetics^ focuses on the
influence of dietary agents on epigenetic mechanisms. This approach has gained considerable attention; since in contrast to
genetic alterations, epigenetic modifications are reversible affect early carcinogenesis. Currently, there is an evident lack of
papers dedicated to the phytochemicals/plant extracts as complex epigenetic modulators, specifically in BC. Our paper highlights
the role of plant natural compounds in targeting epigenetic alterations associated with BC development, progression, as well as its
potential chemoprevention in the context of preventive medicine. Comprehensive measures are stated with a great potential to
advance the overall BC management in favor of predictive, preventive, and personalized medical services and can be considered
as Bproof-of principle^ model, for their potential application to other multifactorial diseases.
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Introduction
Approximately two million new cases and a half of million
deaths registered annually; breast cancer (BC) has reached an
epidemic scale in the early twenty-first century [1]. Poor sur-
vival rates in young asymptomatic patient cohorts such as the
premenopausal triple-negative breast cancer (TNBC) require
new strategies in the overall BC management, focused on
innovative screening programs in young subpopulations, pre-
dictive diagnosis, effective targeted prevention, and custom-
ized treatments [2–5]. Due to the high incidence of BC world-
wide, there is an urgency in oncology research to better un-
derstand the causes of this disease with the aim to improve
clinical strategies and allow the progress in the predictive,
preventive, and personalized medicine.
Mammary carcinogenesis and metastatic disease comprise
both genetic and epigenetic components. In contrast to the ge-
netic (inborn, non-modifiable) component, epigenetic alter-
ations occur permanently being linked with environmental
and lifestyle (modifiable) risk factors which are particularly
important for the development of sporadic BC comprising over
90% of all BC cases worldwide [1]. DNA methylation, histone
chemical modifications, and non-coding RNA (ncRNA)-asso-
ciated multi-gene silencing are considered as key epigenetic
mechanisms governing the cellular homeostasis and differenti-
ation states (Fig. 1). Most of DNA methylation processes are
physiological and essential for human cellular and tissue ho-
meostasis, playing an important role in many key mechanisms.
However, being dysregulated, DNA methylation contributes to
pathologic process such as cancer development and progres-
sion. A global hypomethylation of oncogenes is characteristic
for most of cancer types contributing to the genomic instability
by activating retrotransposons and otherwise silent genomic
regions [6]. On the other hand, hypermethylation of tumor-
suppressor gene promoters plays a specific role in carcinogen-
esis [7, 8]. The overall impact of the epigenetic regulation on
the human body is multifactorial being piloted by several en-
dogenous and exogenous factors such as age, gender, environ-
mental stress factors, lifestyle, diet, and stage of cancer.
A number of studies demonstrated that dietary natural plant
products (both whole products and their compounds) affect the
development and progression of cancer disease including breast
cancer [9–13]. Phytochemicals, as widely available bioactive
substances, have demonstrated apparent anticancer potential
specifically by targeting aberrant epigenetic changes [14, 15].
Cancer risk prediction is rapidly continuing to evolve in medic-
inal practice. In this regard, clinical research can define specific
epigenetic modulations related to the identification of high-risk
individuals [6–8]. Consequently, epigenetic profiling of indi-
viduals can serve in the development of modern clinical strat-
egies with crucial interventions in the primary, secondary, and
tertiary prevention of BC. Furthermore, the integration of rele-
vant epigenetic data associated with complex medical
informatics and personalized medicine is highly recommended
in the BC treatment and management. Medicinal approaches
fall into the progressive concept of advanced health care tai-
lored to the person [1]. BNutri-epigenetics^ focuses on the in-
fluence of dietary agents on epigenetic mechanisms [16]. This
approach has gained considerable attention; since in contrast to
genetic alterations, epigenetic modifications are reversible and
affect early carcinogenesis. Currently, there is an evident lack of
papers dedicated to the phytochemicals/plant extracts as com-
plex epigenetic modulators specifically in BC. Our paper high-
lights the role of plant natural compounds in targeting epige-
netic alterations associated with BC development, progression,
as well as its potential chemoprevention.
Source of data
Data from the available biomedical literature were collected
and analyzed. Relevant studies published in the English-
language literature were retrieved by the use of epigenetics
or breast cancer or predictive preventive and personalised
medicine or DNA methylation or histone chemical modifica-
tions or siRNA or miRNA or lncRNA or phytochemicals or
plant natural substances or plant food or diet as either a key-
word or MeSH (medical subject heading) term in searches of
the PubMed bibliographic database. We focused primarily on
the most recent scientific papers from the years 2013–2018.
1. Aberrant DNA methylation is a hallmark
of cancer
The comparison of DNA methylation levels in cancer tissue
with the DNA methylation in an analogous normal tissue or
DNA methylation in a variety of normal tissues revealed that
cancer cells are very often associated with a global DNA hy-
pomethylation [17, 18]. It is well described that aberrant DNA
methylation affects a plethora of signaling pathways within
transcription of relevant genes, and it leads to abnormalities
in the differentiation of cells [18–20]. The prevailing epige-
netic modification in the eukaryotic nucleus of mammals is
the methylation of DNA at the 5-position of cytosine. This
process is catalyzed by DNA methyltransferases (DNMTs)
using S-adenosyl methionine as a universal donor of methyl
group. Several types of DNMTs were described in eukaryotic
cells. DNMT1 is responsible for maintaining DNA methyla-
tion status in the cell. DNMT2 plays a crucial role in the
process, typically the recognition of DNA damage, DNA re-
pair, or DNA recombination. DNMT3B, DNMT3A, and
DNMT3L are usually upregulated in in malignant cells; these
are responsible for the hypermethylation of tumor-suppressor
genes’ promoters [21]. Sequences of DNA rich on CG repeats,
known as CpG islands, are heavily methylated and act to
maintain chromosomal stability. CpG islands within the
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promoter regions of a gene are generally unmethylated.
Global DNA hypomethylation in CpG islands can lead to
the genomic instability commonly observed in malignant
cells; on the other hand, increased methylation of CpG islands
within the gene promoters can lead to transcriptional silencing
of tumor suppressors [15, 22–25].
Phytochemicals with demethylation activity
in preclinical cancer research
Decrease in the total promoter methylation status of tumor-
suppressor genes has a great potential as molecular target for
cancer therapy. Aberrant DNA methylation patterns that are
frequently observed in sporadic BC represent reversible chang-
es, which are responsive to environmental factors, including
dietary habits [26]. Plant compounds such as phenolics that
can act as hypomethylating agents [25] can reverse epigenetic
silencing of tumor-suppressor genes. For instance, the epige-
netic silencing of glutathione S-transferase P1 is linked to the
pathogenesis of BC and other cancer types. In this regard,
Kumar et al. [25] assessed the epigenetic potential of curcumin
on the methylation pattern of this tumor-suppressor gene in
MCF-7 breast cancer cells. They demonstrated that curcumin
completely reversed the glutathione S-transferase P1 promoter
hypermethylation, and moreover, this modification led to re-
expression of glutathione S-transferase P1. In another in vitro
study, curcumin decreased the promoter methylation of Ras-
association domain family protein 1A (RASSF1A) (TSG) and
increased its mRNA and protein levels in breast cancer MCF-7
cells [27]. Moreover, curcumin decreased DNA methylation
activity of nuclear extract through the downregulation of the
mRNA and protein levels of DNMT1, which may be linked
with curcumin-induced disruption of NF-κB/Sp1 complex
bound to the promoter region of DNMT1. Taken together,
curcumin seems to be an excellent nontoxic hypomethylating
agent with a possible potential against BC. Mirza et al. [28]
hypothesized that epigallocatechin gallate (EGCG), genistein,
withaferin A, curcumin, resveratrol, and guggulsterone are
potential demethylators. Therefore, the effect of these plant
compounds on DNMTs expressions and methylation status of
the panel of genes in MCF-7 and MDA-MB 231 cells was
evaluated. The treatment with various polyphenols showed an
apparent decrease in the transcript levels of DNMT1,
DNMT3A, and DNMT3B in both cell lines. Moreover, these
plant compounds lowered the protein levels of epigenetic reg-
ulators histone deacetylase 1 andMeCP2. Several in vitro stud-
ies showed the epigenetic modulator potential of sulforaphane
in BC. Lewinska et al. [29] evaluated sulforaphane as an epi-
genetic modulator in BC cells (MCF-7, MDA-MB-231, and
SK-BR-3). Sulforaphane caused cell cycle arrest and senes-
cence of cancer cells. Oncostatic characteristics of sulforaphane
were accompanied by global DNAhypomethylation, decreased
levels of DNA methyltransferases (DNMT1, DNMT3B), and
diminished pools of N6-methyladenosine (m6A) RNA methyl-
ation. In another study, combination of sulforaphane with (−)-
epigallocatechin gallate as a demethylating agent was identified
as an effective approach for re-expression of estrogen receptor
in hormone negative BC [30]. Moreover, in the study of diet by
Lubecka-Pietruszewska et al. [31], sulforaphane caused hypo-
methylation of PTEN and RARbeta2 promoters with subse-
quent gene upregulation in MCF-7 and MDA-MB-231 cells.
TNBC is characterized by poor prognosis and a DNA hypome-
thylation profile. An in vitro study by Kala et al. [32] demon-
strated that resveratrol and pterostilbene administered at a dose
(close to physiologically relevance) shows synergistic growth
inhibition on HCC1806 andMDA-MB-157 cells, a TNBC cell
lines [32]. Authors concluded that this result provided a novel
nutrient control strategy that may contribute to future clinical
strategies against relapsed/refractory metastatic TNBC. Szarc
Vel Szic et al. [33] reported that DNA hypermethylation of
corresponding CpG sites in PLAU, ADAM8, TNSF12,
GSTM1, and ME3 genes is linked with receptor tyrosine-
protein kinase erbB-2 amplification (HER2)/estrogen receptor
(ER)/progesterone receptor (PR) status in TNBC.Withaferin A
(WA), a plant-derived steroidal lactone, induced DNA hyper-
methylation of multiple CpG sites which may contribute to
Fig. 1 The relevance of epigenetics in the carcinogenesis. Epigenetic
mechanisms of carcinogenesis consist of three distinct processes: DNA
methylations, histone protein methylations, and acetylations and RNA
mechanisms including aberrant activity of siRNA, miRNA, and
lncRNA. Ac, acetylation; DNMTs, methyltransferases; Me, methylation
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epigenetic reprogramming of genes involved in aggressiveness
of TNBC towards less aggressive luminal-like BC hallmarks.
Verification of gene expression alterations caused by WAwas
performed in MDA-MB-231 and MCF-7 cells. There are sev-
eral other recent papers describing plant extracts or isolated
phytochemicals, such as green tea polyphenols, wild yam root
extract, kazinol Q, genistein, and wild thyme, as demethylating
agents in vitro [34–38].
Several papers reported the analyses of DNA methylation
changes in BC animal models. Rodriguez-Miquel et al. [39]
evaluated the role of nutritional factors, especially dietary
lipids, in the etiology of rat mammary carcinogenesis.
Authors analyzed the global and gene specific (RASSF1A,
TIMP3) DNA methylation levels in mammary glands and
mammary tumors after the administration of olive oil– or corn
oil–enriched diet, respectively. Olive oil, rich in a plethora of
beneficial bioactive compounds and a monounsaturated fats,
elevated the levels of global DNAmethylation in rat mammary
gland and cancer tissue. Corn oil, rich in sterols, polyunsaturat-
ed and monounsaturated fatty acids, increased DNA methyl-
transferase activity in both tissues; moreover, it increased the
promoter methylation of the tumor-suppressor genes
RASSF1A and TIMP3. These results demonstrated differential
effects of the high-fat diets on epigenetic changes in
carcinogen-induced rat mammary carcinogenesis. In this re-
gard, our recent chemoprevention study [40] analyzed the effect
of clove buds on the methylation status in the promoter regions
of RASSF1A (three CpG islands) and TIMP3 (six CpG islands)
genes in rat breast carcinoma cells in vivo. Strong chemopre-
ventive effects of cloves in rats were accompanied with signif-
icant effects on the methylation levels of RASSF1A and
TIMP3 promoters in different CpG islands. However, epigenet-
ic mechanisms of cloves in our study could represent only one
of the plethora mechanisms by which this spice prevented
NMU-induced rat mammary gland carcinogenesis in our study.
Moreover, this result requires more complex experimental val-
idation (e.g., the use of wider spectrum of promoters assessed).
In another study, Wang et al. [41] described new epigenetic
function of isoliquiritigenin, a chalcone-type molecule derived
from licorice root. This natural compound lowered the methyl-
ation levels of WIF1 promoter as the consequence of decreased
DNMT1 activity and thus prevented mouse mammary
cancerogenesis. Epigenetically silenced functions of WIF1
tumor-suppressor gene have been also described in other cancer
types [41]. The role of phytochemicals or plant foods in the
influencing of methylation status of genes’ promotors is sum-
marized in Fig. 2.
Clinical research: dietary intervention and DNA
methylation patterns in breast cancer
Despite preclinical research, only limited clinical data evalu-
ating the effects of phytochemicals on DNA methylation
patterns in BC disease are available. It is well described that
global DNA hypomethylation in the tissue and blood has
been associated with increased cancer risk; on the other
hand, healthier lifestyle patterns have been linked with in-
creased levels of global DNA methylation. Recently,
Greenlee et al. [42] assessed the long-term effects of a
short-term culturally based dietary intervention on increas-
ing fruits/vegetables, decreasing fat, and changing bio-
markers associated with BC recurrence risk among
Hispanic BC survivors. Investigators enrolled 70 women
with a history of stage 0–III BC. After 12 months, the inter-
vention group demonstrated increase in plasma lutein (+
20.4% vs. − 11.5%; P < 0.01) and borderline significant in-
crease in global DNA methylation (+ 0.8% vs. − 0.5%; P =
0.06). Authors concluded that dietary intervention positive-
ly altered the biomarkers linked with BC recurrence risk.
Another clinical study examined the linkage between
changes in lifestyle modifications (diet, weight loss, includ-
ing eating ≥ 2 servings of fruit and ≥ 3 servings of vegeta-
bles), metabolic markers, and global epigenetic biomarkers
using white blood cells [43]. Study participants were
Hispanic, African American, and Afro-Caribbean over-
weight and sedentary female BC survivors (n = 24). Data
were measured at baseline and after 6 and 12 months of
intervention. Investigators evaluated DNA methylation of
long interspersed nucleotide element 1 (LINE-1) and satel-
lite 2 by pyrosequencing and MethyLight, respectively, and
global DNA methylation by the luminometric methylation
assay (LUMA). DNAmethylation of LINE-1 was increased
after 6 months (75.5% vs. 78.5% [P < 0.0001]) and
12 months (75.5% vs. 77.7% [P < 0.0001]) in comparison
with baseline. Importantly, 12-month changes in dietary
measures such as vegetable intake were positively associat-
ed with changes in LUMA DNA methylation, as was intake
of fruit positively associated with changes in LINE-1 DNA
methylation [43]. Hypermethylation of RARB (retinoic ac-
id receptor-beta), BRCA1, and RASSF1A promoters was
linked with the downregulation of transcript levels in the
relevant gene in primary BC. In this regard, Pirouzpanah
et al. [44] assessed the hypermethylation status in 146 dis-
sected BC tissue samples in Iranian women using
methylation-specific PCR. A validated 136-item food fre-
quency questionnaire was used as a method for the estima-
tion of dietary nutrients. The intake of folate and cobalamin
was inversely associated with methylated RARB and
BRCA1. On the other hand, higher dietary intake of ribo-
flavin and pyridoxine was linked with increased methyla-
tion in the RARB promoter. Moreover, authors concluded
with evidence for age-dependent effects of nutrients on pro-
moter methylation status.
Table 1 summarizes the role of phytochemicals targeting
epigenetic changes linked with DNA methylation patterns in
breast carcinogenesis.
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2. Chemoprevention by histone chemical
modifications
Histones are proteins that order and package DNA into nucle-
osomes. Tightly packedDNA regions called heterochromatins
are less accessible for transcription factors and are thus inac-
tive in the term of gene expression, whereas lightly packed
euchromatin regions are active. Modifications of histones are
covalent post-translational changes of histone amino acid res-
idues located in their N- and C-terminal tails [45, 46]. They
include acetylation, methylation, phosphorylation,
ubiquitylation, sumoylation, and ADP ribosylation and are
achieved by diverse histone-modifying enzymes (HATs,
HDACs, HMTs, HDMs, and others) grouped in several clas-
ses. Elevated levels of global histone acetylation and methyl-
ation have been found in majority of luminal-like breast tu-
mors and have been associated with a favorable prognosis.
Moderate and low levels of lysine acetylation (H3K9ac,
H3K18ac, H4K12ac) and lysine and arginine di-/three-meth-
ylations (H3K4me2, H4K20me3, H4R3me2) were found in
BC subtypes with poorer prognosis, including basal carcino-
mas and HER2-positive tumors [47, 48]. Study ofMüller et al.
[49] revealed significantly different expression of class I his-
tone deacetylases (HDAC) in human BC. HDAC1 expression
was elevated in hormone receptor–positive tumors, while
HDAC2 and HDAC3 were expressed significantly higher in
low differentiated tumors and correlated with negative hor-
mone receptor status. Moreover, high HDAC2 expression
was associated with an overexpression of HER2 and nodal
metastasis.
Aberrant histone modifications and changed expression of
histone-modifying enzymes are caused by genetic mutations
in chromatin regulators enzymes and by epigenetic changes.
Dietary phytochemicals, like epigallocatechin-3-gallate
(EGCG), curcumin, garcinol, antioxidant vitamins, and fla-
vones, are able to modulate epigenetic modifications and thus
are actively involved in chemoprevention [50–54]. The mech-
anisms of the chemical modifications of histones caused by
phytochemicals are shown in Fig. 3.
Histone acetylation
Histone chemical modifications including acetylations are
commonly analyzed in BC. Clinical analyses of Elsheikh
Fig. 2 Mechanism of enhanced tumor-suppressor gene expression
through increased promoter demethylation using isolated plant-derived
compounds or plant foods. DNMTs, DNA methyltransferases; TET,
ten-eleven translocation protein; 5mC, 5-methylcytosine; 5hmC, 5-
hydroxymethylcytosine
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et al. [48] discovered low or absent H4K16ac in the majority
of BC cases in humans (78.9%), proposing that this change
may denote an early sign of breast carcinoma. Histone acety-
lation is enzymatic addition of an acetyl group (COCH3) from
acetyl coenzyme A. This process is involved in the regulation
of many cellular processes such gene silencing, cell cycle
progression, apoptosis, differentiation, and DNA repair
[55–57]. The modifying enzymes are called histone acetyl-
transferases (HATs) and histone deacetylaces (HDACs).
Epigallocatechin-3-gallate (EGCG) is a major component of
green tea polyphenols. It has important anticancer activity via
epigenetic mechanisms and play important role in induction of
apoptosis, anti-oxidation and inhibition of proliferation, angio-
genesis, andmetastasis [58–60]. Li et al. [61] studied the role of
EGCG treatment in ERα-negative MDA-MB-231 breast
cancer cells. ERα-negative BC is clinically aggressive and
has a poor prognosis because it normally does not respond to
conventional anti-hormone therapies. They proved that EGCG
can induce re-expression of endogenous estrogen receptor α
(ERα). The reactivation is regulated via chromatin remodeling
of the ERα promoter by altering histone acetylation and meth-
ylation status. EGCG was found to decrease binding of the
transcription repressor complex in the promoter region of
ERα Rb/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 contrib-
uting to ERα transcriptional activation. The effect was even
enhanced when EGCG was combined with the histone
deacetylase (HDAC) inhibitor, trichostatin A (TSA). Meeran
et al. [62] analyzed epigenetic impact of EGCG on the
hTERT expression in human breast cancer cells MCF-7 (ER+)
and MDA-MB-231 (ER−). EGCG treatment of these cell lines
Table 1 Natural substances targeting DNA methylations associated with breast cancer
Phytochemicals/plant foods Mechanism of intervention Type of BC research References
Curcumin Decrease in promoter methylation status (RASSF1A,
glutathione S-transferase P1) or DNA methylation
activity




Decrease in DNMT1, DNMT3a, and DNMT3b
expressions
MCF-7 and MDA-MB 231 cells [28]
Sulforaphane Global DNA hypomethylation, decrease in DNMT1
and DNMT3 activity, and m6A RNA methylation
MCF-7 MDA-MB 231, and SK-BR-3
cells
[29]
Sulforaphane + EGCG ERα promoter hypomethylation and hyperacetylation MDA-MB 231 cells [30]
Sulforaphane PTEN and RARbeta2 promoter hypomethylation MCF-7 and MDA-MB 231 cells [31]
Resveratrol + pterostilbene Decrease in DNMTs activity HCC1806 and MDA-MB-157 breast
cancer cells
[32]
Withaferin A Epigenetic reprogramming through DNA
hypermethylation
MDA-MB-231, MCF-7 cells [33]
Green tea polyphenols
+5-aza-2′-deoxycytidine
Decrease in HDAC1, DNMT1, DNMT3b, and
MBD4 activity
MDA-MB-231, MCF-7 cells [34]
Kazinol Q Inhibition of DNMT1 activity MDA-MB-231 cells [36]
Genistein Decrease in global DNA methylation, DNMT activity,
and DNA methylation of several promoters (ATM,
APC, PTEN, SERPINB5)
MCF-7 and MDA-MB-231 cells [37]
Wild yam root extract Activation of GATA3 gene in ER- cells MCF-7 and MDA-MB-231 cells [35]
Wild thyme Inhibition of DNMT and HDAC activities MDA-MB-231 cells [38]
Isoliquiritigenin Demethylation of WIF1 promoter, decrease in
DNMT1 activity
Mouse BC model [41]
Olive oil Increase in global DNA methylation Rat BC model [39]
Corn oil Increase in DNMT methylation and promoter
methylation of RASSF1A and TIMP3
Rat BC model [39]
Clove buds (mixture of phenolic
acids, flavonol glucosides,
tannins and phenolic volatile
oils – eugenol, acetyl eugenol)
Increase in total RASSF1A promoter methylation Rat BC model [40]
Fruits/vegetables Increase in global DNA methylation Hispanic BC survivors [42]
Vegetables Increase in DNA methylation of LINE-1 after 6
and 12 months




Folate + cobalamin Hypomethylation of RARB and BRCA1 promoters BC tissue samples of Iranian women [44]
Riboflavin + pyridoxine Hypermethylation of RARB promoter BC tissue samples of Iranian women [44]
EGCG, epigallocatechin gallate; DNMT, DNA methyltransferase; ER, estrogen receptor; HDAC, histone deacetylase; MBD, methyl-CpG-binding
domain
408 EPMA Journal (2018) 9:403–419
significantly inhibited HATs activities, but not HDACs activi-
ties. They found an EGCG-induced time dependent decrease of
transcriptional active chromatin markers such as H3ac,
H3K9ac, and H4ac. Deacetylation induced by EGCG further
recruits hTERT transcriptional repressors such as E2F-1 and
MAD1, contributing to inhibition of hTERT expression; what
resulted in cellular apoptosis induction is similar in both ER (+)
and ER (−) human breast cancer cells but not in normal cells
[62]. Besides the described impact of EGCG on the histone
acetylation status, this metabolite exerted its anticancer effect
also by correcting other epigenetic alterations in cancer cells
such as polycomb-group (PcG) protein–dependent histone
methylation, DNA methylation, class-I HDACs-dependent
deacetylation of histones, and some non-histone proteins and
ubiquitination [63].
A similar histone acetylation level reduction was reported
in the case of curcumin and garcinol in human breast prolif-
erating MCF7 cells. H3 and H4 acetylation was reduced after
exposure to curcumin, garcinol, or garcinol derivate LTK 14,
although pan-acetylation of H4 indicated differential and
dose-dependent effects of these compounds on histone modi-
fications in MCF7 cells [64]. Increased H3 acetylation was
found in the study of Weng et al. [50] who analyzed newly
identified flavone, 3,4′-dimethoxy-3′,5,7-trihydroxyflavone
from the plantMyoporum bontioides in human MCF-7 breast
cancer cells. This phytochemical downregulates the expres-
sion of histone deacetylase 2 (HDAC2) and HDAC4, leading
to increased histone H3 acetylation and p21 upregulation. It is
involved in the cell cycle regulation and growth inhibition of
MCF-7 cells and 3,4′-dimethoxy-3′,5,7-trihydroxyflavone
thus possess the similar antiproliferative activity as the
EGCG and genistein [50]. Secoiridoids, a family of complex
polyphenols found in extra virgin olive oil also appear to in-
fluence the histone acetylation. Study of the unique BC cell
line JIMT-1, specific for inherently exhibition of cross-
resistance to multiple HER1/2-targeted drugs, showed histone
hyperacetylation. As these phenols should efficiently circum-
vent de novo resistance to HER1/2 inhibitors, they could rep-
resent novel anti-breast cancer molecules [65].
Several other studies were conducted in the term of histone
acetylation modulation by phytochemical compounds. The
analyses revealed their antitumor activity as they act as
HDAC inhibitors. Among them, the attention has been paid
to diallyl disulphide (DADS), the major organosulfur com-
pound found in garlic oil [66]; isothiocyanates, found in crucif-
erous vegetables [67]; luteolin (3′,4′,5,7-tetrahydroxyflavone),
a member of the flavonoid family found in various fruits and
vegetables [68] and to triterpenoid 5β,19-epoxy-19-
methoxycucurbita-6,23-dien-3β,25-diol [69].
Histone methylation
Histone methylation is defined as the transfer of one, two, or
three methyl groups (me1, me2, or me3) to histone proteins,
Fig. 3 The role of plant
compounds in the chemical
modification of histones.
Phytochemicals affect the
functions of KMTs, KDMs,
HDACs, HATs, and DNMTs and




remodeling protein complex. It is
able to restructure the nucleosome
to make its DNA accessible
during transcription, replication,
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which can be methylated on lysine (K) and arginine (R) resi-
dues [70]. The most commonly observed methylation is on
lysine residues of histone tails H3 and H4. The transfer of S-
adenosyl-L-methionine is catalyzed by histone methyltransfer-
ases (HMTs) which are specific for lysine and arginine resi-
dues [71]. Methylation of histones can either increase or de-
crease transcription of genes, depending onwhich amino acids
in the histones are methylated and how many methyl groups
are attached. It seems that histone methylation marks are
coupled with the pathology of BC, as Rivenbark et al. [70]
showed differential levels of histone methylation in several of
the cancer cell lines when compared to a normal mammary
epithelial cell line. BT549 and SUM102 cells exhibited low
levels of H3K4me3 and increased levels of H3K36me3. In
addition, alterations in methylation of histone lysines such as
H3K4m3, H3K9m3, and H4K20m3 have been frequently as-
sociated with breast carcinoma [71]. Moreover, the loss of
histone H4K20 trimethylation has been documented as a
marker of poor prognosis in breast carcinoma patients and is
linked with the invasiveness of breast carcinoma cells in a
HER2-independent manner [72].
The role of plant natural substances on the histone methyl-
ation patterns has been documented in several in vitro and
in vivo studies [10, 73, 74]. For example, garcinol also affects
the processes of histone methylation and the trimethylation of
H4K20 (H4K20me3) in MCF7 breast cancer cells. Authors
found that this is due to the induced expression of
SUV420H2, an enzyme that specifically trimethylate H4K20
[64]. Dagdemir et al. [75] showed that soy phytoestrogens
(da idze in , gen is te in , equol , 17β -es t rad io l , and
suberoylanilide hydroxamic acid) are able to modulate gene
transcription via the acetylation and demethylation of histones
in six genes (BRCA1, EZH2, ERα, ERβ, P300, and SRC3) in
MCF-7 and MDA-MB 231 cancer cells. Genistein represents
natural compound with a multi-targeted biological/molecular
activities, including epigenetic histone chemical modifications
in carcinoma cells. In another experimental study, genistein
reactivated expression of ERα through the histone modifica-
tion in the ERα promoter and the inhibition of histone
deacetylase inhibitors in MDA-MB-231 and MDA-MB-157
cells [74]. Results of Li et al. [76] demonstrated that genistein
suppressed cell proliferation in human breast precancerous
and cancer cells; on the other hand, it showed only slight effect
on normal breast epithelial cells. Moreover, genistein admin-
istration upregulated the expression of p21(WAF1) (p21) and
p16(INK4a) (p16) tumor-suppressor genes and downregulat-
ed the expression of BMI1 and c-MYC tumor promoting
genes. Genistein induced histone chemical modifications in
p21 and p16 promoters and affected the binding of the c-
MYC-BMI1 complex to the p16 promoter resulting in the
stimulation of such tumor-suppressor genes. As well, the au-
thors administered genistein (250 mg/kg of diet) to mice, and
these doses corresponded to daily consumption of soybean
products in humans. The results confirmed significant impact
of genistein on the tumor growth from the very early stages.
There are only few experimental BC studies describing the
role of whole plant-based foods in the chemical modulations
of histones. We have found only two papers assessing the
effect of dietary factors on histone chemical modifications in
rat mammary carcinogenesis. The results of our group showed
that dietary administered clove buds significantly and dose-
dependently increased the levels of H4K20m3 (and also
H4K16ac) in chemically induced cancers [40]. We did not
find the changes in chemical modifications of three methyla-
tions of H3K4 and H3K9. Our results could be considered as a
one of plethora mechanisms by which phytochemicals from
cloves may prevent nitrosomethylurea-induced mammary
gland carcinogenesis in female rats, however, our results await
further experimental validation (e.g., with wider spectrum of
histone chemical modifications or gene promoters analyzed).
Results from similar rat model also pointed to significant ef-
fect of extra virgin olive oil on H4K20m3 levels in mammary
tumors or glands [39].
As indicated above (summarization in Table 2), histone-
modifying methods and enzymes interact with each other as
well as with other chromatin related proteins and other epige-
netic mechanisms, which makes the issue of histone modifi-
cations complex and extensive. Therefore, more research is
needed to find out exact pathways of phytochemical impact
and to find out proper benefits in utilizing in the cancer risk
reduction.
3. Plant-derived compounds in breast cancer
prevention and therapy: RNA level
of intervention
Recent experimental and clinical BC studies focused on
influencing the epigenome have provided convincing evi-
dence that plant-derived compounds participate in regulation
of genes through affecting non-coding RNAs (ncRNAs), es-
pecially microRNAs (miRNAs) and long non-coding RNAs
(lncRNAs) [77–84]. miRNAs together with short (or small)-
interfering RNAs (siRNAs) are two main types of small
ncRNAs, which regulate gene expression through the RNA
interference (RNAi) mechanism [85]. Currently, it is well
known that RNAi plays important regulatory role in the pro-
cess of normal cell development and differentiation, as well as
in the process of carcinogenesis. RNAi may also be potential
therapeutic device to shut down upregulated oncogenes, mu-
tated tumor-suppressor (TS) genes, and other genes involved
in tumor progression within targeted gene therapy in cancer
patients [86, 87]. Recent studies suggest that synthetic
siRNAs and endogenous miRNAs may influence transcrip-
tional gene silencing by promoting histone deacetylation,
DNA, and histone methylation [88, 89]. However, CpG
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methylation of selected miRNAs and inhibition of histone
deacetylases may lead to changes in miRNA expression in
cancer cells [90]. As well, phytochemicals may act as inhibitors
of DNA methyltransferases and histone deacetylases, and in
this way, they can reactivate for example methylation-silenced
TS genes or miRNAs controlling TS genes [89, 91, 92].
RNA interference is a natural mechanism of RNA-
dependent gene silencing in which small RNA molecules in-
hibit expression and translation of protein-coding genes bear-
ing either fully or partially complementary sequence [93, 94].
The classical RNAi pathway is triggered by long double-
stranded RNA (dsRNAs) precursors such as long dsRNA or
short hairpin RNA (shRNA). These precursors are processed
into siRNAs by the RNase III enzyme termed Dicer [86, 95,
96]. The siRNAs then bind to an enzyme-containing molecule
known as RNA-induced silencing complex (RISC). The
siRNA-RISC or miRNA-RISC complex leads to the recogni-
tion and ultimately the cleavage or translational repression of
complementary single-stranded RNAs (mRNAs or viral
genomic/antigenomic RNAs) [86, 95, 96]. Taken together,
siRNAs as well as miRNAs are able degrade mRNA and
inhibit its expression by very similar mechanisms. Plethora
preclinical studies showed that plant-derived compounds
modulating the RNA-based epigenetic mechanisms may have
considerable importance in BC prevention and therapy.
Short-interfering RNAs
Despite the fact that RNAi seems to be promising in in vitro
cancer research, it presents some limitations in vivo. Short
RNAs have low stability due to RNase degradation; therefore,
their nontoxic delivery into deep tissues is still problematic.
Other limitations are also low potential to overpass the mem-
branes, stimulation of innate immune response, or the error
rate of Boff-target^ interactions [97, 98]. The first study, which
overcame these limitations and brought good evidence for
clinical utility of RNAi-based therapeutics in patients with
advanced cancer disease, used lipid nanoparticle approach
[99]. To date, siRNA nanoparticles were used in some preclin-
ical studies of various types of BC [100–104] and have paved
the way for clinical trials [105].
Regarding the plant-based compounds, siRNA mecha-
nisms and BC, there are only limited data available in data-
bases. Physapubenolide (PB) is a cytotoxic withanolide
Table 2 Natural substances inducing histone chemical modifications associated with breast cancer
Phytochemicals/plant foods Mechanism of intervention Type of BC research References
EGCG Alteration of histone acetylation and methylation
status, ERα reactivation
MDA-MB-231 cells [61]
EGCG Inhibition of HATs activities, hTERT promoter
hypomethylation and histone deacetylations
(acetyl-H3, acetyl-H3K9, and acetyl-H4)
MCF-7, MDA-MB-231 cells [62]
Curcumin and garcinol, Reduction in H3K18ac (garcinol), elevated global
levels of H4K16ac and H4K20m3 (garcinol),




from Myoporum bontioides L.
Downregulation of HDAC2 and HDAC4 expression,
increase of H3ac
MCF-7 cells [50]
Secoiridoids Histone hyperacetylation JIMT-1 cells [65]
Diallyl disulphide/garlic oil HDAC inhibition MCF-7 cells [66]





from Momordica charantia L.
Downregulation of HDAC1, increase in H3ac MCF-7 [69]
Soy phytoestrogens (isoflavones) Histones demethylation and acetylation (H3K27me3,
H3K9me3, H3K4me3, H4K8ac, and H3K4ac)
MCF-7 and MDA-MB 231 cells [75]
Genistein Histones modification in theERα promoter,
reactivation of ERα expression
Mouse BC model using
MDA-MB-231 cells
[74]
Genistein Histone modifications in the promoters of p21 and
p16 genes
HMECs, SH, SHR, MDA-MB-231 [76]
Clove buds (mixture of phenolic acids,
flavonol glucosides, tannins and phenolic
volatile oils – eugenol, acetyl eugenol)
Increase in lysine trimethylations and acetylations
(H4K20me3, H4K16ac)
Rat BC model [40]
Extra virgin olive oil Decrease in H4K20m3 levels in mammary tumors
or glands
Rat BC model [39]
EGCG, epigallocatechin gallate; ER, estrogen receptor; HDAC, histone deacetylase; HAT, histone acetyltransferase
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present in Physalis angulata that is used as a traditional
Chinese medicine. Ma et al. [106] evaluated the role of
TIGAR (TP53-inducible glycolysis and apoptosis regulator)
and ROS in PB-induced apoptosis and autophagosome forma-
tion in MDA-MB-231 and MCF-7 cancer cells. Investigators
described that the downregulation of TIGAR by siRNA was
augmented with low concentrations of PB. These effects were
associated with induced apoptosis and autophagosome forma-
tion, which led to the anti-tumor effect of PB in vitro [106].
Another study showed that phosphatase and tensin homolog
(PTEN) is a key target of bergapten (psoralen derivative pres-
ent in many fruits and vegetables) action against BC cells for
the induction of autophagy. The mechanism of action in-
volved the p38MAPK/NF-Ypathway, site-direct mutagenesis
of NF-Y element, and NF-Y siRNA regulation [107].
Anticancer effects were also exhibited by honokiol, a phyto-
chemical from Magnolia spp., which caused a reduction in
cell migration of murine BC cells through the COX-2
siRNA mechanism [108]. There are also other in vitro studies
using plant-derived compounds pointing to siRNA mecha-
nism influencing mammary carcinogenesis [109–111].
MicroRNAs
Several recent preclinical and clinical BC studies demon-
strated that isolated phytochemicals or their mixture influ-
ence the expression of oncogenic or tumor-suppressive
miRNAs, which, in turn, modulate the important signaling
pathways in cancer cells and in this way affect the patho-
genic properties of cancer cells and their sensitivity towards
anticancer drugs. Stilbenoid resveratrol belongs among in-
tensively evaluated molecules in BC research [112]. In the
study of Hagiwara et al. [78], resveratrol upregulated sev-
eral tumor-suppressive miRNAs (miR-16, miR-141, miR-
143, and others) in MDA-MB-231 breast cancer cell line
resulting in the induction of an anti-tumor effect against
the cancer stem-like cells phenotype in cancer cells. In
other experimental study, resveratrol inhibited DNA-
methyltransferase DNMT3b in rat mammary tumors by up-
regulation of miR-129, miR-204, and miR-489 [113]. Other
in vitro studies showed that tumor-suppressive miR-34a is
an essential component of the antiproliferative activities of
phytochemicals such as I3C and artemisinin [82]. Curcumin
regulated the expression of several miRNAs in MCF-7
(miR-19a, miR-19b, miR-181b), MDA-MB-231, and
MDA-MB-435 breast cancer cells (miR-34a) [114–116].
Currently, drug resistance is considered a main factor
influencing BC clinical outcome. Dysregulated miRNAs
contribute significantly to autophagy and chemoresistance.
Therefore, targeting autophagy-related miRNAs is a novel
strategy to reverse drug resistance. In the study of Wang
et al. [117], natural compound isoliquiritigenin induced
the chemosensitization drug-resistant BC cells through
inhibition of the novel autophagy-related miR-25 in both
in vitro and in vivo assays. Isolated phytochemicals were
able to affect the levels of miRNAs in other experimental
in vitro studies as well [79, 80, 83].
In addition, the experimental approach using mixtures of
phytochemicals seems to be very promising in the positive
modulation of miRNAs expression regarding the BC cells.
Rhodes et al. [77] evaluated the anticancer activity of
glyceollin mixture using theMDA-MB-231 xenograft mod-
el. Glyceollins significantly increased the expression of se-
lected tumor-suppressive miRNAs (miR-22, miR-29b,
miR-29c, miR-30d, miR-34a, miR-181c, miR-181d, and
miR-195) and significantly decreased the expression of sev-
eral oncogenic miRNAs (miR-21, miR-185, and miR-224).
Banerjee et al. [118] showed in their experimental study in
BC that the anticancer effects of pomegranate polyphenol
extract were partially the result of downregulation of two
miRNAs, miR-155 and miR-27a, using MDA-MB-231 and
BT-474 cell lines, and BT474 xenografts in nude mice. In
the recent study, blueberry delayed the tumor latency and
reduced tumor volume and multiplicity in 17β-estradiol-
mediated mammary carcinogenesis in female ACI rats par-
tially through modulation of miR-18a and miR-34c levels
[119]. In the study of Su et al. [119], the Chinese traditional
medicine Antrodia cinnamomea showed significant anti-
CSCs effects in several cancer cell lines, including MDA-
MB-231 cells, through significant downregulation of select-
ed oncogenic miRNAs in BC stem cells [120]. The clinical
study of Guo et al. [84] assessed the linkage of soy intake
with the expression of microRNAs (miRNAs) and genes in
the tumor tissue of 272 women with TNBC. Thirteen of the
14 miRNAs, including tumor-suppressive miR-29a-3p,
manifested overexpression in women with high soy intake.
Authors concluded that long-term soy food intake is asso-
ciated with the specific expression of selected miRNAs and
has protective effect against BC risk in TNBC patients.
Long non-coding RNAs
Comprehensive research has shown that lncRNAs demon-
strate crucial role in the modulation of gene expression at
the level of chromatin, transcriptional, and posttranscriptional
modifications [121, 122]. In the case of epigenetic modifica-
tions, previous experimental and clinical evaluations have
showed that DNA methylation and modifications of histone
result in deregulation of lncRNA expression in mammary tu-
mors [123–127]. Regarding transcriptional modulation,
lncRNAs interfere with the expression of high number of gene
via interacting with chromatin at numerous different locations
across multiple chromosomes [128]. Posttranscriptional regu-
lation through lncRNAs includes modulation of mRNA sta-
bility, cell cycle distribution, and cell differentiation [127,
129]. To date, several recent preclinical and clinical
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oncological studies have shown that specific lncRNAs have a
significant association with mammary carcinogenesis [124,
126, 130–143]. Some lncRNAs have great potential to be
reliable biomarkers in the diagnosis, prognosis, and prediction
of BC, or could be effectively used within anticancer therapy
of this disease.
So far, few BC studies have dealt with the influence of
plant natural substances on expression and/or function of
lncRNAs. Chen et al. [81] demonstrated that genistein and
calycosin were able to inhibit the expression of the onco-
genic HOTAIR lncRNA in ER+ breast cancer cell line
MCF-7. In other study using the xenograft BC model
(MDA-MB-231-Luc-GFP breast cancer cells in athymic
mice), the levels of HOTAIR lncRNAs were downregulated
by using of anthocyanin delphinidin-3-glucoside [144].
Further studies in this field of research are necessary.
Results of these studies may provide important information
regarding the influence of phytochemicals on lncRNAs,
which are significantly associated with BC and thus may
help to improve prevention and therapeutic strategies in this
disease. Qu et al. [145] described that compound Kushen
injection (CKI), a complex mixture of plant secondary me-
tabolites present in traditional Chinese medicine, shows sig-
nificant anticancer effects in MCF-7 lines. Authors found
that many lncRNAs were expressed as a response to CKI
treatment.
The mechanism of action of plant-derived compounds or
plant foods involving siRNA, miRNA, and lncRNA regula-
tion in breast carcinogenesis is summarized in Fig. 4.
4. Concluding remarks and outlook
Dietary habits and phytochemicals are of particular interest in
terms of effective cancer prevention and targeted therapy
[146, 147]. Many of plant-derived natural compounds
Fig. 4 Mechanism of action of phytochemicals involving non-coding
RNA regulations within breast carcinogenesis. See text for indicated
changes as each displayed axis represents the findings of presented
studies. Arrows demonstrate specific effect of phytochemicals in female
breast cancer model; ↑induction/upregulation, ↓inhibition/reduction.
DNMT3b, DNA(cytosine-5-)-methyltransferase 3 beta; Mcl-1, induced
myeloid leukemia cell differentiation protein; PTEN, phosphatase and
tensin homolog; TIGAR, TP53-inducible glycolysis and apoptosis
regulator; T-S, tumor-suppressive
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demonstrated significant anticancer properties through multi-
ple cell signaling pathways and mechanisms. Regarding BC,
its chemoprevention and targeted therapies, an application of
the dietary phytochemicals, is demonstrated as cost-effective
and readily applicable clinical approach. The pivotal role of
epigenetic mechanisms (DNAmethylations, histone chemical
modifications, and non-coding RNAs) has been demonstrat-
ed: epigenetic modifications by phytochemicals may play an
important role in the targeted cancer chemoprevention. The
demonstrated low toxicity of phytochemicals is crucial for
their broad application. Noteworthy, most of the bioactive
plant compounds demonstrate more than one epigenetic tar-
get. Consequently, a dual beneficial effect can be expected by
upregulating tumor-suppressor genes and downregulating on-
cogenes. Further, a multidrug administration (combination of
several plant compounds) may be more effective compared to
the application of individual phytochemicals. This approach
might lead to substantial progress made in the development of
effective chemopreventive and therapeutic modalities. In this
regard, Tables 1 and 2, and Fig. 4 summarize currently avail-
able information within BC research.
Despite the extensive research focused on human epige-
nome, there is still insufficient experimental data published
on the epigenetic alterations induced by plant compounds.
Moreover, most of the data in this topic are of preclinical
nature, which are linked with several limitations within
clinical practice. The future research focused on phyto-
chemicals influencing the human epigenome should be di-
rected within the several issues: (a) Novel data demand
more detailed insight on the molecular mechanisms re-
sponsible for these effects. (b) The next essential step is
to determine an effective (individual) dose of dietary phy-
tochemicals. The doses used in preclinical research in vitro
and in vivo is to be taken with caution, because such high
concentrations of phytochemicals might not be achievable
in humans, and consequently might lack clinical benefits.
In this respect, the synthesis of chemical analogues of ac-
tive substances could be very helpful. (c) It might be useful
to extend the spectrum of relevant phytochemicals by cur-
rently untested isolated molecules, extracts, and/or whole
plant products. (d) Assessing the combined effects of sev-
eral plant compounds targeting several relevant epigenetic
pathways could be a promising strategy for future epige-
netic experiments. (e) Modifying sub-optimal epigenomes
by phytochemicals in order to regulate the expression of
key inflammatory genes may be an effective approach by
immunotherapy. (f) Investigating epigenetic mechanisms
induced by plant compounds linked with the cancer stem
cells survival could provide important tool for oncologist
in the management of cancer disease, regarding the relapse
or multidrug resistance. Moreover, Bepigenetic therapy^
might have a great potential to overcome drug resistance
and/or to re-sensitize cancer cells towards chemotherapy.
(g) An improved bioavailability of phytochemicals (for
example, by utilizing nanomaterial complexes) should be
furtherly considered. (h) An administration of plant com-
pounds either for chemoprevention or treatment of the clin-
ically manifested BC represents an attractive approach en-
hancing the efficacy of conventional therapies. (i) The
plant compounds demonstrate cel l - , organ- , and
organism-specific effects; therefore, better understanding
of the target mechanisms and individual characteristics is
a big challenge for scientists to develop personalized sup-
plements. Currently preferred diagnostic approaches are in
many cases unable to identify early stages of cancer
initiation/promotion that impairs clinical outcomes [148].
Innovative screening programs, multiomic diagnostics in-
cluding evaluation of epigenetic changes (such as global
DNA and gene promoters methylation status, histone
chemical modifications, and miRNAs expressions), and
individualized patient profiling and stratification are cru-
cial clinical approaches to target and start personalized
preventive programs in high-risk individuals [149, 150].
Each epigenetic mechanism is predicted to have many mo-
lecular targets [151] and therefore may be regulated by
plethora of specific phytochemicals or plant foods. The
applicability of major phytochemicals/foods as an Bepi-
drugs^ against cancer disease is already experimentally
established and has great potential to open a new area of
individualized healthcare in the clinical medicine [152].
The above stated measures have a great potential to ad-
vance the overall BC management in favor of predictive,
preventive, and personalized medical services and can be
considered as the Bproof-of principle^ model for their po-
tential application to other multifactorial diseases.
Authors’ contribution PK contributed to conception of the idea, literature
search, manuscript drafting and editing and SU, ZD, AK, PS, MS, KK,
MK, MP, and BZ contributed to literature search and manuscript drafting.
VV sketched and drew the figures. OG and TKK contributed to concep-
tion of the idea and edited themanuscript. AZ, PZ, DB, and JD revised the
manuscript with critical reviews and comments and all the authors ap-
proved the final version.
Funding information This work was supported by the Scientific Grant
Agency of the Ministry of Education of the Slovak Republic under the
contracts no. VEGA 1/0108/16, 1/0018/16 and the Slovak Research and
Development Agency under the contract no. APVV-16-0021.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Statement of informed consent Patients have not been involved in the
study.
Statement of human and animal rights No experiments have been
performed including patients and/or animals.
414 EPMA Journal (2018) 9:403–419
References
1. Golubnitschaja O, Debald M, Yeghiazaryan K, KuhnW, Pešta M,
Costigliola V, et al. Breast cancer epidemic in the early 21st cen-
tury: evaluation of risk factors, cumulative questionnaires and rec-
ommendations for preventive measures. Tumor Biol. 2016;37:
12941–57.
2. Polivka J Jr, Kralickova M, Polivka J Jr, Kaiser C, Kuhn W,
Golubnitschaja O. Mystery of the brain metastatic disease in
breast cancer patients: improved patient stratification, dis-
ease prediction and targeted prevention on the horizon?
EPMA J. 2017;8:119–27. https://doi.org/10.1007/s13167-
017-0087-5.
3. Golubnitschaja O. Feeling cold and other underestimated symp-
toms in breast cancer: anecdotes or individual profiles for ad-
vanced patient stratification? EPMA J. 2017;8:17–22.
4. Zubor P, Gondova A, Polivka J Jr, Kasajova P, Konieczka K,
Danko J, et al. Breast cancer and Flammer syndrome: any symp-
toms in common for prediction, prevention and personalised med-
ical approach? EPMA J. 2017;8:129–40.
5. Bubnov R, Polivka J Jr, Zubor P, Koniczka K, Golubnitschaja O.
BPre-metastatic niches^ in breast cancer: are they created by or
prior to the tumour onset? BFlammer syndrome^ relevance to ad-
dress the question. EPMA J. 2017;8:141–57.
6. Hon GC, Hawkins RD, Caballero OL, Lo C, Lister R, Pelizzola
M, et al. Global DNA hypomethylation coupled to repressive
chromatin domain formation and gene silencing in breast cancer.
Genome Res. 2012;22:246–58.
7. Ng JM, Yu J. Promoter hypermethylation of tumour suppressor
genes as potential biomarkers in colorectal cancer. Int J Mol Sci.
2015;16:2472–96.
8. Akhavan-Niaki H, Samadani AA. DNA methylation and cancer
development: molecular mechanism. Cell Biochem Biophys.
2013;67(2):501–13.
9. Li Y, Li S, Meng X, Gan RY, Zhang JJ, Li HB. Dietary natural
products for prevention and treatment of breast cancer. Nutrients.
2017. https://doi.org/10.3390/nu9070728.
10. Shukla S, Meeran SM, Katiyar SK. Epigenetic regulation by se-
lected dietary phytochemicals in cancer chemoprevention. Cancer
Lett. 2014;355:9–17.
11. Shapira N. The potential contribution of dietary factors to breast
cancer prevention. Eur J Cancer Prev. 2017;26:385–95.
12. Giacosa A, Barale R, Bavaresco L, Gatenby P, Gerbi V, Janssens J,
et al. Cancer prevention in Europe: the Mediterranean diet as a
protective choice. Eur J Cancer Prev. 2013;22:90–5.
13. Simopoulos AP. The traditional diet of Greece and cancer. Eur J
Cancer Prev. 2004;13:219–30.
14. Nagaprashantha LD, Adhikari R, Singhal J, Chikara S, Awasthi S,
Horne D, et al. Translational opportunities for broad-spectrum
natural phytochemicals and targeted agent combinations in breast
cancer. Int J Cancer. 2017. https://doi.org/10.1002/ijc.31085.
15. Khan S, Shukla S, Sinha S, Meeran SM. Epigenetic targets in
cancer and aging: dietary and therapeutic interventions. Expert
Opin Ther Targets. 2016;20:689–703.
16. Shankar E, Kanwal R, CandamoM, Gupta S. Dietary phytochem-
icals as epigenetic modifiers in cancer: promise and challenges.
Semin Cancer Biol. 2016;40-41:82–99.
17. Varley KE, Gertz J, Bowling KM, Parker SL, Reddy TE, Pauli-
Behn F, et al. Dynamic DNA methylation across diverse human
cell lines and tissues. Gen Res. 2013;23:555–67.
18. Veland N, Hardikar S, Zhong Y, Gayatri S, Dan J, Strahl BD, et al.
The arginine methyltransferase PRMT6 regulates DNA methyla-
tion and contributes to global DNA hypomethylation in cancer.
Cell Rep. 2017;21:3390–7.
19. Heichman KA, Warren JD. DNA methylation biomarkers and
their utility for solid cancer diagnostics. Clin Chem Lab Med.
2012;50:1707–21.
20. EhrlichM, LaceyM. DNAmethylation and differentiation: silenc-
ing, upregulation and modulation of gene expression.
Epigenomics. 2013;5:553–68.
21. Subramaniam D, Thombre R, Dhar A, Anant S. DNA methyl-
transferases: a novel target for prevention and therapy. Front
Oncol. 2014;4:80.
22. Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP,
Gao X, et al. Aberrant CpG-island methylation has non-random
and tumour-type-specific patterns. Nat Genet. 2000;24:132–8.
23. Ehrlich M, Jiang G, Fiala E, Dome JS, Yu MC, Long TI, et al.
Hypomethylation and hypermethylation of DNA in Wilms tu-
mors. Oncogene. 2002;21:6694–702.
24. Berman BP,Weisenberger DJ, Aman JF, Hinoue T, Ramjan Z, Liu
Y, et al. Regions of focal DNA hypermethylation and long-range
hypomethylation in colorectal cancer coincide with nuclear
lamina-associated domains. Nat Genet. 2012;44:40–6.
25. Kumar U, Sharma U, Rathi G. Reversal of hypermethylation and
reactivation of glutathione S-transferase pi 1 gene by curcumin in
breast cancer cell line. Tumour Biol. 2017;39:101042831769225.
https://doi.org/10.1177/1010428317692258.
26. Zhang L, Long X. Association of BRCA1 promoter methylation
with sporadic breast cancers: evidence from 40 studies. Sci Rep.
2015;5:17869.
27. Du L, Xie Z, Wu LC, Chiu M, Lin J, Chan KK, et al. Reactivation
of RASSF1A in breast cancer cells by curcumin. Nutr Cancer.
2012;64:1228–35.
28. Mirza S, Sharma G, Parshad R, Gupta SD, Pandya P, Ralhan R.
Expression of DNAmethyltransferases in breast cancer patients and
to analyze the effect of natural compounds on DNAmethyltransfer-
ases and associated proteins. J Breast Cancer. 2013;16:23–31.
29. Lewinska A, Adamczyk-Grochala J, Deregowska A, Wnuk M.
Sulforaphane-induced cell cycle arrest and senescence are accom-
panied by DNA hypomethylation and changes in microRNA pro-
file in breast cancer cells. Theranostics. 2017;7:3461–77.
30. Meeran SM, Patel SN, Li Y, Shukla S, Tollefsbol TO. Bioactive
dietary supplements reactivate ER expression in ER-negative
breast cancer cells by active chromatin modifications. PLoS
One. 2012;7:e37748.
31. Lubecka-Pietruszewska K, Kaufman-Szymczyk A, Stefanska B,
Cebula-Obrzut B, Smolewski P, Fabianowska-Majewska K.
Sulforaphane alone and in combination with clofarabine epigenet-
ically regulates the expression of DNA methylation-silenced tu-
mour suppressor genes in human breast cancer cells. J Nutrigenet
Nutrigenomics. 2015;8:91–101.
32. Kala R, Shah HN, Martin SL, Tollefsbol TO. Epigenetic-based
combinatorial resveratrol and pterostilbene alters DNA damage
response by affecting SIRT1 and DNMT enzyme expression, in-
cluding SIRT1-dependent γ-H2AX and telomerase regulation in
triple-negative breast cancer. BMC Cancer. 2015;15:672.
33. Szarc Vel Szic K, Declerck K, Crans RAJ, Diddens J, Scherf DB,
Gerhäuser C, et al. Epigenetic silencing of triple negative breast
cancer hallmarks by withaferin A. Oncotarget. 2017;8:40434–53.
34. Tyagi T, Treas JN, Mahalingaiah PK, Singh KP. Potentiation of
growth inhibition and epigenetic modulation by combination of
green tea polyphenol and 5-aza-2′-deoxycytidine in human breast
cancer cells. Breast Cancer Res Treat. 2015;149:655–68.
35. Aumsuwan P, Khan SI, Khan IA, Avula B, Walker LA, Helferich
WG, et al. Evaluation of wild yam (Dioscorea villosa) root extract
as a potential epigenetic agent in breast cancer cells. In Vitro Cell
Dev Biol Anim. 2015;51:59–71.
36. Weng JR, Lai IL, Yang HC, Lin CN, Bai LY. Identification of
kazinol Q, a natural product from Formosan plants, as an inhibitor
of DNA methyltransferase. Phytother Res. 2014;28:49–54.
EPMA Journal (2018) 9:403–419 415
37. Xie Q, Bai Q, Zou LY, Zhang QY, Zhou Y, Chang H, et al.
Genistein inhibits DNA methylation and increases expression of
tumor suppressor genes in human breast cancer cells. Genes
Chromosom Cancer. 2014;53:422–31.
38. Bozkurt E, Atmaca H, Kisim A, Uzunoglu S, Uslu R, Karaca B.
Effects of Thymus serpyllum extract on cell proliferation, apopto-
sis and epigenetic events in human breast cancer cells. Nutr
Cancer. 2012;64(8):1245–50.
39. Rodríguez-Miguel C, Moral R, Escrich R, Vela E, Solanas M,
Escrich E. The role of dietary extra virgin olive oil and corn oil
on the alteration of epigenetic patterns in the rat DMBA-induced
breast cancer model. PLoS One. 2015;10:e0138980.
40. Kubatka P, Uramova S, Kello M, Kajo K, Kruzliak P, Mojzis J,
et al. Antineoplastic effects of clove buds (Syzygium aromaticum
L.) in the model of breast carcinoma. J Cell Mol Med. 2017;21:
2837–51.
41. Wang N, Wang Z, Wang Y, Xie X, Shen J, Peng C, et al. Dietary
compound isoliquiritigenin prevents mammary carcinogenesis by
inhibiting breast cancer stem cells through WIF1 demethylation.
Oncotarget. 2015;6:9854–76.
42. Greenlee H, Ogden Gaffney A, Aycinena AC, Koch P, Contento I,
Karmally W, et al. Long-term diet and biomarker changes after a
short-term intervention among Hispanic breast cancer survivors:
the ¡Cocinar Para Su Salud! randomized controlled trial. Cancer
Epidemiol Biomark Prev. 2016;25:1491–502.
43. Delgado-Cruzata L, Zhang W, McDonald JA, Tsai WY,
Valdovinos C, Falci L, et al. Dietary modifications, weight loss,
and changes in metabolic markers affect global DNAmethylation
in Hispanic, African American, and Afro-Caribbean breast cancer
survivors. J Nutr. 2015;4:783–90.
44. Pirouzpanah S, Taleban FA, Mehdipour P, Atri M. Association of
folate and other one-carbon related nutrients with hypermethylation
status and expression of RARB, BRCA1, and RASSF1A genes in
breast cancer patients. J Mol Med (Berl). 2015;93:917–34.
45. Füllgrabe J, Kavanagh E, Joseph B. Histone onco-modifications.
Oncogene. 2011;30:3391–403.
46. Esteller M. Cancer epigenomics: DNA methylomes and histone-
modification maps. Nat Rev Genet. 2007;8:286–98.
47. Chervona Y, Costa M. Histone modifications and cancer: bio-
markers of prognosis? Am J Cancer Res. 2012;2:589–97.
48. Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA,
Collins HM, et al. Global histone modifications in breast cancer
correlate with tumor phenotypes, prognostic factors, and patient
outcome. Cancer Res. 2009;69:3802–9.
49. Müller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies
J, et al. Differential expression of histone deacetylases HDAC1, 2
and 3 in human breast cancer–overexpression of HDAC2 and
HDAC3 is associated with clinicopathological indicators of dis-
ease progression. BMC Cancer. 2013;13:215.
50. Weng JR, Bai LY, LinWY, Chiu CF, Chen YC, Chao SW, et al. A
flavone constituent from Myoporum bontioides induces M-phase
cell cycle arrest of MCF-7 breast cancer cells. Molecules.
2017a;22:472.
51. Mirabella AC, Foster BM, Berke T. Chromatin deregulation in
disease. Chromosoma. 2016;125:75–93.
52. Bathaie SZ, Tmanoi F. Mechanism of the anticancer effect of
phytochemicals (the enzymes), 1st edn. Elsevier Inc.; 2015.
53. Busch CH, Burkard M, Leischner CH, Lauer UM, Frank J,
Venturelli S. Epigenetic activities of flavonoids in the prevention
and treatment of cancer. Clin Epigenetics. 2015;7:64.
54. Hardy TM, Tollefsbol TO. Epigenetic diet: impact on the epige-
nome and cancer. Epigenomics. 2011;3:503–18.
55. Messier TL, Gordon JAR, Boyd JR, Tye CE, Browne G, Stein JL,
et al. Histone H3 lysine 4 acetylation and methylation dynamics
define breast cancer subtypes. Oncotarget. 2016;7:5094–109.
56. Cohen I, Poreba E, Kamieniarz K, Schneider R. Histone modifiers
in cancer. Friends or foes? Genes Cancer. 2011;2:631–47.
57. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene.
2007;26:5420–32.
58. Yiannakopoulou ECH. Effect of green tea catechins on breast
carcinogenesis: a systematic review of in-vitro and in-vivo exper-
imental studies. Eur J Cancer Prev. 2014;23:84–9.
59. Thangapazham R, Singh A, Sharma A, Warren J, Gaddipati J,
Maheshwari R. Green tea polyphenols and its constituent epigallo-
catechin gallate inhibits proliferation of human breast cancer cells
in vitro and in vivo. Cancer Lett. 2007;245:232–41.
60. Mittal A, Pate MS, Wylie RC, Tollefsbol TO, Katiyar SK. EGCG
down-regulates telomerase in human breast carcinoma MCF-7
cells, leading to suppression of cell viability and induction of
apoptosis. Int J Oncol. 2004;24:703–10.
61. Li Y, Yuan YY,Meeran SM, Tollefsbol TO. Synergistic epigenetic
reactivation of estrogen receptor-α (ERα) by combined green tea
polyphenol and histone deacetylase inhibitor in ERα-negative
breast cancer cells. Mol Cancer. 2010;9:274.
62. Meeran SM, Patel SH, Chan TH, Tollefsbol TO. A novel prodrug
of epigallocatechin-3-gallate: differential epigenetic hTERT re-
pression in human breast cancer cells. Cancer Prev Res (Phila).
2011;4:1243–54.
63. Thakur VS, Deb G, Babcook MA, Gupta S. Plant phytochemicals
as epigenetic modulators: role in cancer chemoprevention. AAPS
J. 2014;16:151–63.
64. Collins HM, Abdelghany MK, Messmer M, Yue B, Deeves SE,
Kindle KB, et al. Differential effects of garcinol and curcumin on
histone and p53 modifications in tumour cells. BMC Cancer.
2013;13:37.
65. Oliveras-Ferraros C, Fernández-Arroyo S, Vazquez-Martin AV.
Crude phenolic extracts from extra virgin olive oil circumvent de
novo breast cancer resistance to HER1/HER2-targeting drugs by
inducing GADD45-sensed cellular stress, G2/M arrest and
hyperacetylation of histone H3. Int J Oncol. 2011;38:1533–47.
66. Altonsy MO, Habib TN, Andrews SC. Diallyl disulfide-induced
apoptosis in a breast-cancer cell line (MCF-7) may be caused by
inhibition of histone deacetylation. Nutr Cancer. 2012;64:1251–60.
67. Nian H, Delage B, Ho E, Dashwood RH. Modulation of histone
deacetylase activity by dietary isothiocyanates and allyl sulfides:
studies with sulforaphane and garlic organosulfur compounds.
Environ Mol Mutagen. 2009;50:213–21.
68. Attoub S, Hassan AH, Vanhoecke B, Iratni R, Takahashi T, Gaben
AM, et al. Inhibition of cell survival, invasion, tumor growth and
histone deacetylase activity by the dietary flavonoid luteolin in
human epithelioid cancer cells. Eur J Pharmacol. 2011;651:18–25.
69. Weng JR, Bai LY, Lin WY. Identification of a triterpenoid as a
novel PPARγ activator derived from Formosan plants. Phytother
Res. 2017b;31:1722–30.
70. Rivenbark AG, Coleman WB, Stahl BD. Histone methylation
patterns in human breast cancer. FASEB J. 2009;23:S38.1.
71. Greer EL, Shi Y. Histone methylation: a dynamic mark in health,
disease and inheritance. Nat Rev Genet. 2012;13:343–57.
72. Yokoyama Y, Matsumoto A, Hieda M, Shinchi Y, Ogihara E,
Hamada M, et al. Loss of histone H4K20 trimethylation predicts
poor prognosis in breast cancer and is associated with invasive
activity. Breast Cancer Res. 2014;16:R66.
73. PudenzM, Roth K, Gerhauser C. Impact of soy isoflavones on the
epigenome in cancer prevention. Nutrients. 2014;6:4218–72.
74. Li Y, Meeran SM, Patel SN, Chen H, Hardy TM, Tollefsbol TO.
Epigenetic reactivation of estrogen receptor-α (ERα) by genistein
enhances hormonal therapy sensitivity in ERα-negative breast
cancer. Mol Cancer. 2013;12:9.
75. Dagdemir A, Durif J, Ngollo M, Bignon YJ, Bernard-Gallon D.
Histone lysine trimethylation or acetylation can be modulated by
416 EPMA Journal (2018) 9:403–419
phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines.
Epigenomics. 2013;5:51–63.
76. Li Y, Chen H, Hardy TM, Tollefsbol TO. Epigenetic regulation of
multiple tumor-related genes leads to suppression of breast tumor-
igenesis by dietary genistein. PLoS One. 2013;8:e54369.
77. Rhodes LV, Tilghman SL, Boue SM. Glyceollins as novel targeted
therapeutic for the treatment of triple-negative breast cancer.
Oncol Lett. 2012;3:163–71.
78. Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F,
Ochiya T. Stilbene derivatives promote Ago2- dependent tumour-
suppressive microRNA activity. Sci Rep. 2012;2:314.
79. Ahmad A, Ali S, Ahmed A, Ali AS, Raz A, Sakr WA, et al. 3, 3′-
Diindolylmethane enhances the effectiveness of Herceptin against
HER-2/neu- expressing breast cancer cells. PLoS One. 2013;8:
e54657.
80. Li X, Xie W, Xie C, Huang C, Zhu J, Liang Z, et al. Curcumin
modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-
induced MCF-7 breast cancer cell proliferation. Phytother Res.
2014;28:1553–60.
81. Chen J, Lin C, Yong W, Ye Y, Huang Z. Calycosin and genistein
induce apoptosis by inactivation of HOTAIR/p-Akt signaling
pathway in human breast cancer MCF-7 cells. Cell Physiol
Biochem. 2015;35:722–8.
82. Hargraves KG, He L, Firestone GL. Phytochemical regulation of
the tumor suppressive microRNA, miR-34a, by p53-dependent
and independent responses in human breast cancer cells. Mol
Carcinog. 2016;55:486–98.
83. de la Parra C, Castillo-Pichardo L, Cruz-Collazo A, Cubano L,
Redis R, Calin GA, et al. Soy isoflavone genistein-mediated
downregulation of miR-155 contributes to the anticancer effects
of genistein. Nutr Cancer. 2016;68:154–64.
84. Guo X, Cai Q, Bao P, Wu J, Wen W, Ye F, et al. Long-term soy
consumption and tumor tissue MicroRNA and gene expression in
triple-negative breast cancer. Cancer. 2016;122:2544–51.
85. Yeung ML, Jeang KT. MicroRNAs and cancer therapeutics.
Pharm Res. 2011;28:3043–9.
86. AbdelrahimM, Safe S, Baker C, Abudayyeh A. RNAi and cancer:
implications and applications. J RNAi Gene Silenc. 2006;2:136–
45.
87. Mansoori B, Sandoghchian Shotorbani S, Baradaran B. RNA in-
terference and its role in cancer therapy. Adv Pharm Bull. 2014;4:
313–21.
88. Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic
mechanisms and role in cardiovascular disease. Circulation.
2011;123:2145–56.
89. Kong AN, Zhang C, Su ZY. Targeting epigenetics for cancer pre-
vention by dietary cancer preventive compounds–the case of
miRNA. Cancer Prev Res. 2013;6:622–4.
90. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid
alteration of microRNA levels by histone deacetylase inhibition.
Cancer Res. 2006;66:1277–81.
91. Papoutsis AJ, Lamore SD, Wondrak GT, Selmin OI, Romagnolo
DF. Resveratrol prevents epigenetic silencing of BRCA-1 by the
aromatic hydrocarbon receptor in human breast cancer cells. J
Nutr. 2010;140:1607–14.
92. Vaid M, Prasad R, Singh T, Jones V, Katiyar SK. Grape seed
proanthocyanidins reactivate silenced tumor suppressor genes in
human skin cancer cells by targeting epigenetic regulators.
Toxicol Appl Pharmacol. 2012;263:122–30.
93. Petrocca F, Lieberman J. Promise and challenge of RNA
interference-based therapy for cancer. J Clin Oncol. 2011;29:
747–54.
94. Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering
RNAs can inhibit mRNA expression by similar mechanisms.
Proc Natl Acad Sci U S A. 2003;100:9779–84.
95. Meister G, Tuschl T. Mechanisms of gene silencing by double-
stranded RNA. Nature. 2004;431:343–9.
96. Parvani JG, Jackson MW. Silencing the roadblocks to effective
triple-negative breast cancer treatments by siRNA nanoparticles.
Endocr Relat Cancer. 2017;24:R81–97.
97. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and
challenges. Adv Drug Deliv Rev. 2007;59:75–86 100.
98. Young SW, Stenzel M, Yang JL. Nanoparticle-siRNA: a potential
cancer therapy? Crit Rev Oncol Hematol. 2016;98:159–69.
99. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz
GK, Weiss GJ, et al. First-in-humans trial of an RNA interference
therapeutic targeting VEGF and KSP in cancer patients with liver
involvement. Cancer Discov. 2013;3:406–17.
100. Deng ZJ, Morton SW, Ben-Akiva E, Dreaden EC, Shopsowitz
KE, Hammond PT. Layer-by-layer nanoparticles for systemic
codelivery of an anticancer drug and siRNA for potential triple-
negative breast cancer treatment. ACS Nano. 2013;7:9571–784.
101. Feng Q, Yu MZ, Wang JC, Hou WJ, Gao LY, Ma XF, et al.
Synergistic inhibition of breast cancer by co-delivery of VEGF
siRNA and paclitaxel via vapreotide-modified core-shell nanopar-
ticles. Biomaterials. 2014;35:5028–38.
102. Liu Y, Zhu YH, Mao CQ, Dou S, Shen S, Tan ZB, et al. Triple
negative breast cancer therapy with CDK1 siRNA delivered by
cationic lipid assisted PEG-PLA nanoparticles. J Control Release.
2014;192:114–21.
103. Parvani JG, Gujrati MD, Mack MA, Schiemann WP, Lu ZR.
Silencing β3 integrin by targeted ECO/siRNA nanoparticles in-
hibits EMTand metastasis of triple-negative breast cancer. Cancer
Res. 2015;75:2316–25.
104. Su S, Tian Y, Li Y, Ding Y, Ji T, Wu M, et al. BTriple-punch^
strategy for triple negative breast cancer therapy with minimized
drug dosage and improved antitumor efficacy. ACSNano. 2015;9:
1367–78.
105. Schultheis B, Strumberg D, Santel A, Vank C, Gebhardt F, Keil O,
et al. First-in-human phase I study of the liposomal RNA interfer-
ence therapeutic Atu027 in patients with advanced solid tumors. J
Clin Oncol. 2014;32:4141–8.
106. Ma T, Zhang Y, Zhang C, Luo JG, Kong LY. Downregulation of
TIGAR sensitizes the antitumor effect of physapubenolide
through increasing intracellular ROS levels to trigger apoptosis
and autophagosome formation in human breast carcinoma cells.
Biochem Pharmacol. 2017;143:90–106.
107. De Amicis F, Aquila S, Morelli C, Guido C, Santoro M, Perrotta I,
et al. Bergapten drives autophagy through the up-regulation of
PTEN expression in breast cancer cells. Mol Cancer. 2015;14:130.
108. Singh T, Katiyar SK. Honokiol, a phytochemical from Magnolia
spp., inhibits breast cancer cell migration by targeting nitric oxide
and cyclooxygenase-2. Int J Oncol. 2011;38:769–76.
109. Hahm ER, Lee J, Singh SV. Role of mitogen-activated protein
kinases andMcl-1 in apoptosis induction bywithaferin a in human
breast cancer cells. Mol Carcinog. 2014;53:907–16.
110. Marconett CN, Sundar SN, Poindexter KM, Stueve TR, Bjeldanes
LF, Firestone GL. Indole-3-carbinol triggers aryl hydrocarbon
receptor-dependent estrogen receptor (ER)alpha protein degrada-
tion in breast cancer cells disrupting an ERalpha-GATA3 tran-
scriptional cross-regulatory loop. Mol Biol Cell. 2010;21:1166–
77.
111. Nguyen HH, Aronchik I, Brar GA, Nguyen DH, Bjeldanes LF,
Firestone GL. The dietary phytochemical indole-3-carbinol is a
natural elastase enzymatic inhibitor that disrupts cyclin E protein
processing. Proc Natl Acad Sci U S A. 2008;105:19750–5.
112. Kisková T, Jendželovský R, Rentsen E, Maier-Salamon A,
Kokošová N, Papčová Z, et al. Resveratrol enhances the chemo-
preventive effect of celecoxib in chemically induced breast cancer
in rats. Eur J Cancer Prev. 2014;23:506–13.
EPMA Journal (2018) 9:403–419 417
113. Qin W, Zhang K, Clarke K, Weiland T, Sauter ER. Methylation
and miRNA effects of resveratrol on mammary tumors vs. normal
tissue. Nutr Cancer. 2014;66:270–7.
114. Li Q, Eades G, Yao Y, Zhang Y, Zhou Q. Characterization of a
stem-like subpopulation in basal-like ductal carcinoma in situ
(DCIS) lesions. J Biol Chem. 2014;289:1303–12.
115. Kronski E, Fiori ME, Barbieri O, Astigiano S, Mirisola V, Killian
PH, et al. miR181b is induced by the chemopreventive polyphenol
curcumin and inhibits breast cancer metastasis via down-
regulation of the inflammatory cytokines CXCL1 and −2. Mol
Oncol. 2014;8:581–95.
116. Guo J, Li W, Shi H, Xie X, Li L, Tang H, et al. Synergistic effects
of curcumin with emodin against the proliferation and invasion of
breast cancer cells through upregulation of miR-34a. Mol Cell
Biochem. 2013;82:103–11.
117. Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie T, et al. MicroRNA-
25 regulates chemoresistance-associated autophagy in breast can-
cer cells, a process modulated by the natural autophagy inducer
isoliquiritigenin. Oncotarget. 2014;5:7013–26.
118. Banerjee N, Talcott S, Safe S, Mertens-Talcott SU. Cytotoxicity of
pomegranate polyphenolics in breast cancer cells in vitro and vivo:
potential role of miRNA-27a and miRNA-155 in cell survival and
inflammation. Breast Cancer Res Treat. 2012;136:21–34.
119. Jeyabalan J, Aqil F, Munagala R, Annamalai L, Vadhanam MV,
Gupta RC. Chemopreventive and therapeutic activity of dietary
blueberry against estrogen-mediated breast cancer. J Agric Food
Chem. 2014;62:3963–71.
120. Su YK, Shih PH, Lee WH, Bamodu OA, Wu ATH, Huang CC,
et al. Antrodia cinnamomea sensitizes radio−/chemo-therapy of
cancer stem-like cells by modulating microRNA expression. J
Ethnopharmacol. 2017;207:47–56.
121. Dong J, Xu J, Wang X, Jin B. Influence of the interaction between
long noncoding RNAs and hypoxia on tumorigenesis. Tumour
Biol. 2016;37:1379–85.
122. Zhang M, Gu H, Xu W, Zhou X. Down–regulation of lncRNA
MALAT1 reduces cardiomyocyte apoptosis and improves left ven-
tricular function in diabetic rats. Int J Cardiol. 2016;203:214–6.
123. Augoff K, McCue B, Plow EF, Sossey-Alaoui K. miR-31 and its
host gene lncRNA LOC554202 are regulated by promoter hyper-
methylation in triple-negative breast cancer. Mol Cancer. 2012;11:5.
124. Lo PK, Zhang Y, Wolfson B, Gernapudi R, Yao Y, Duru N, et al.
Dysregulation of the BRCA1/long non- coding RNA NEAT1 sig-
naling axis contributes to breast tumorigenesis. Oncotarget.
2016;7:65067–89.
125. Lu L, Zhu G, Zhang C, Deng Q, Katsaros D, Mayne ST, et al.
Association of large noncoding RNA HOTAIR expression and its
downstream intergenic CpG island methylation with survival in
breast cancer. Breast Cancer Res Treat. 2012;136:875–83.
126. Shen X, Xie B,Ma Z, YuW,WangW,XuD, et al. Identification of
novel long non-coding RNAs in triple-negative breast cancer.
Oncotarget. 2015;6:21730–9.
127. Vennin C, Spruyt N, Robin YM, Chassat T, Le Bourhis X,
Adriaenssens E. The long non-coding RNA 91H increases aggres-
sive phenotype of breast cancer cells and up-regulates H19/IGF2
expression through epigenetic modifications. Cancer Lett.
2017;385:198–206.
128. Wang L, Chen Z, An L, Wang Y, Zhang Z, Guo Y, et al. Analysis
of long non-coding RNA expression profiles in non-small cell
lung cancer. Cell Physiol Biochem. 2016;38:2389–400.
129. Hayes EL, Lewis-Wambi JS. Mechanisms of endocrine resistance
in breast cancer: an overview of the proposed roles of noncoding
RNA. Breast Cancer Res. 2015;17:40.
130. Lei B, Xu SP, Liang XS, Li YW, Zhang JF, Zhang GQ, et al. Long
non-coding RNA MVIH is associated with poor prognosis and
malignant biological behavior in breast cancer. Tumour Biol.
2016;37:5257–64.
131. Wang G, Liu C, Deng S, Zhao Q, Li T, Qiao S, et al. Long non-
coding RNAs in regulation of human breast cancer. Brief Funct
Genomics. 2016;15:222–6.
132. Xu SP, Zhang JF, Sui SY, Bai NX, Gao S, Zhang GW, et al.
Downregulation of the long non- coding RNA EGOT correlates
with malignant status and poor prognosis in breast cancer. Tumour
Biol. 2015;36:9807–12.
133. Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE,
Hearn S, et al. Differentiation of mammary tumors and reduction
in metastasis upon Malat1 lncRNA loss. Genes Dev. 2016;30:34–
51.
134. Huang YS, Chang CC, Lee SS, Jou YS, Shih HM. Xist reduction
in breast cancer upregulates AKT phosphorylation via HDAC3-
mediated repression of PHLPP1 expression. Oncotarget. 2016;7:
43256–66.
135. Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, et al. The LINK-A
lncRNA activates normoxic HIF1alpha signalling in triple-
negative breast cancer. Nat Cell Biol. 2016;18:213–24.
136. Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X, et al. A cytoplasmic
NF-kappaB interacting long noncoding RNA blocks Ikappa B
phosphorylation and suppresses breast cancer metastasis. Cancer
Cell. 2015;27:370–81.
137. Ma C, Shi X, Zhu Q, Li Q, Liu Y, Yao Y, et al. The growth arrest-
specific transcript 5 (GAS5): a pivotal tumor suppressor long non-
coding RNA in human cancers. Tumour Biol. 2015;37:1437–44.
138. Redis RS, Sieuwerts AM, LookMP, Tudoran O, Ivan C, Spizzo R,
et al. CCAT2, a novel long non-coding RNA in breast cancer:
expression study and clinical correlations. Oncotarget. 2013;4:
1748–62.
139. Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, Bai XZ. LncRNA-ATB
promotes trastuzumab resistance and invasion-metastasis cascade
in breast cancer. Oncotarget. 2015;6:11652–63.
140. Sorensen KP, Thomassen M, Tan Q, Bak M, Cold S, Burton M,
et al. Long non-coding RNAHOTAIR is an independent prognos-
tic marker of metastasis in estrogen receptor-positive primary
breast cancer. Breast Cancer Res Treat. 2013;142:529–36.
141. Wang L, Li J, Zhao H, Hu J, Ping Y, Li F, et al. Identifying the
crosstalk of dysfunctional pathways mediated by lncRNAs in
breast cancer subtypes. Mol BioSyst. 2016;12:711–20.
142. Zhang Y, He Q, Hu Z, Feng Y, Fan L, Tang Z, et al. Long non-
coding RNALINP1 regulates repair of DNA double-strand breaks
in triple- negative breast cancer. Nat Struct Mol Biol. 2016;26:
522–30.
143. Zhang Z, Weaver DL, Olsen D, deKay J, Peng Z, Ashikaga T,
et al. Long non-coding RNA chromogenic in situ hybridisation
signal pattern correlation with breast tumour pathology. J Clin
Pathol. 2016;69:76–81.
144. Yang X, Luo E, Liu X, Han B, Yu X, Peng X. Delphinidin-3-
glucoside suppresses breast carcinogenesis by inactivating the
Akt/HOTAIR signaling pathway. BMC Cancer. 2016;16:423.
145. Qu Z, Cui J, Harata-Lee Y, Aung TN, Feng Q, Raison JM, et al.
Identification of candidate anti-cancer molecular mechanisms of
compound Kushen injection using functional genomics.
Oncotarget. 2016;7:66003–19.
146. Bubnov RV, Spivak MY, Lazarenko LM, Bomba A, Boyko NV.
Probiotics and immunity: provisional role for personalized diets
and disease prevention. EPMA J. 2015;6(1):14.
147. Cauchi JP, Camilleri L, Scerri C. Environmental and lifestyle risk
factors of breast cancer inMalta-a retrospective case-control study.
EPMA J. 2016;7:20.
148. Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun
M, Debald M, et al. Risk assessment, disease prevention and
personalised treatments in breast cancer: is clinically qualified
integrative approach in the horizon? EPMA J. 2013;4(1):6.
149. Fröhlich H, Patjoshi S, Yeghiazaryan K, Kehrer C, Kuhn W,
Golubnitschaja O. Premenopausal breast cancer: potential clinical
418 EPMA Journal (2018) 9:403–419
utility of a multi-omics based machine learning approach for pa-
tient stratification. EPMA J. 2018;9(2):175–86.
150. Smokovski I, Risteski M, Polivka J Jr, Zubor P, Konieczka
K, Costigliola V, et al. Postmenopausal breast cancer:
European challenge and innovative concepts. EPMA J.
2017;8(2):159–69.
151. Sacco K, Grech G. Actionable pharmacogenetic markers for pre-
diction and prognosis in breast cancer. EPMA J. 2015;6(1):15.
152. Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R,
Kapalla M, et al. Medicine in the early twenty-first century: para-
digm and anticipation - EPMA position paper 2016. EPMA J.
2016;7:23.
EPMA Journal (2018) 9:403–419 419
